A Phase 3 interventional study of Memantine and Placebo in Alzheimer's Disease, sponsored by H. Lundbeck A/S. Terminated at 23 sites in Canada. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2013-12-05.
Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing memantine in Alzheimer Disease — 1 open to participants now, 2 under way, none of them phase 3. Memantine · Alzheimer Disease.
Among the 34 studies testing memantine in Alzheimer Disease, this one is the 4th largest by enrollment, is one of 2 that started in 2003, is one of 8 in phase 3, and was the 18th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →1 of the 34 studies testing memantine in Alzheimer Disease is open now, in 1 country. Recruiting first, the newest first:
University Hospitals Cleveland Medical Center · Sites in United States
Ages 18–32
By country, each count listing its studies:
Memantine: first FDA approval 2003 (NAMENDA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 9 · Phase 4 21
First in 2003; this study’s year is marked. 2 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 369 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 90 across the 34 interventional studies. Of the 28 that completed or were terminated, 15 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 34 have an industry lead sponsor. The 10 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
16 studies in Alzheimer Disease by H. Lundbeck A/S: none open now, none under way, none of them phase 3. Of 16 finished, 8 (50%) have results posted.
Among the 16 studies in Alzheimer Disease by H. Lundbeck A/S, this one is the 5th largest by enrollment, is the only one that started in 2003, is one of 6 in phase 3, and was the 2nd registered.
H. Lundbeck A/S’s Alzheimer Disease studies by the year they started, since 2003.
1 of the studies testing memantine in Alzheimer Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05063851University of VirginiaThe Use of Memantine for Prevention of Alzheimer's Disease | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 34 studies testing memantine in Alzheimer Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among H. Lundbeck A/S’s 16 in Alzheimer Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to examine the efficacy of memantine on cognition and behavioural symptoms in outpatients with moderate to severe dementia of the Alzheimer's type.
Memantine is a moderate affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist. Pre-clinical studies have demonstrated that memantine can decrease the neuronal toxicity associated with excessive glutamate release and calcium overload in neurons. Results from clinical trials in patients with moderate to severe Alzheimer's Disease (AD) have demonstrated memantine's efficacy and safety by showing positive treatment effects on cognitive, global and functional decline.
This 24-week randomised, double-blind, placebo-controlled, multicentre study examines the effect of memantine 20 mg, administered once daily, on cognitive and behavioural symptoms in outpatients diagnosed with moderate to severe AD and significant psychopathology.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Outpatients who:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Memantine
Drug: Placebo
20 mg Oral Tablets Once Daily
Also known as: Ebixa®
Oral Tablets Once Daily
Efficacy of Memantine on Behavioural Symptoms in Outpatients With Moderate to Severe Dementia of the Alzheimer's Type Using the NPI - 12 Items Version Total Score.
Change from Baseline in Neuropsychiatric Inventory (NPI) total score. NPI is a validated scale that assesses behavioural disturbances in patients with dementia. The 12 item version consists of 10 behavioural and 2 neurovegetative areas. It provides both a total score as well as scores for a number of sub-scales. The frequency, severity and caregiver distress for each domain are measured. The NPI is based upon responses obtained from the caregiver. The total score is from 0 to 144. A higher score reflects more frequency and severity of the disturbances.
Time frame: Baseline to Week 24
Efficacy of Memantine on Cognition in Outpatients With Moderate to Severe Dementia of the Alzheimer's Type Using the SIB Total Score.
Change from Baseline in Severe Impairment Battery (SIB) total score. SIB is a validated scale used to assess cognitive function in patients with moderate to severe dementia. Items are single words or one-step commands combined with gestures. Nine domains are assessed, and the total score is between 0 and 100. A lower total score reflects the loss of cognitive function.
Time frame: Baseline to Week 24
Efficacy of Memantine on Global Condition Using CIBIC-plus.
Clinician's Interview-Based Impression of Change-Plus Version (CIBIC-plus). Improvement evaluated with reference to Baseline. CIBIC-plus is a global rating that is derived through an independent, comprehensive interview with the patient and caregiver by a rater who is barred from knowledge of all other psychometric test scores conducted as part of this protocol as well as from reported safety data. The rating is made on a 7-point scale ranging from "1 = marked improvement" to "7 = marked worsening". A score of "4" indicates no change.
Time frame: Baseline to Week 24
Efficacy of Memantine on Functioning Using ADCS-ADL - 19 Items Total Score.
Change from Baseline on the Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) 19-item version total score. ADCS-ADL- 19 items version for moderate to severe AD will measure patient's functioning. This battery of ADL questions is used here to measure the functional capabilities of patients with dementia. The inventory is done by interviewing a person in close contact with the patient and covers the most usual and consistent performance of the patient over the preceding 4 weeks. Total score is from 0 to 54. The higher score, the lower impairment.
Time frame: Baseline to Week 24
Efficacy of Memantine on Functioning Using CMAI - Long Form Total Score.
Change from Baseline on the Cohen-Mansfield Agitation Inventory (CMAI) - Long Form total score. CMAI - Long Form looks specifically at agitated behaviour in patients with cognitive impairment. It is a seven-point rating scale assessing the frequency of up to 29 agitated behaviours, ranging from "1 = Never" to "7 = Several times an hour". Rating is based on responses obtained from interviews with the caregiver. The total score ranges from 29 to 203, with a higher score reflecting more frequent behavioural disturbances.
Time frame: Baseline to Week 24
The patients were recruited from the investigators' outpatient clinics.
| Milestone | Memantine | Placebo |
|---|---|---|
| Started | 182 | 187 |
| Completed | 151 | 155 |
| Not completed | 31 | 32 |
| Withdrew: Adverse event | 15 | 10 |
| Withdrew: Non-compliance | 1 | 1 |
| Withdrew: Protocol violation | 2 | 2 |
| Withdrew: Withdrawal of consent | 10 | 7 |
| Withdrew: Nursing home placement | 2 | 9 |
| Withdrew: Other reasons | 1 | 3 |
Change from Baseline in Neuropsychiatric Inventory (NPI) total score. NPI is a validated scale that assesses behavioural disturbances in patients with dementia. The 12 item version consists of 10 behavioural and 2 neurovegetative areas. It provides both a total score as well as scores for a number of sub-scales. The frequency, severity and caregiver distress for each domain are measured. The NPI is based upon responses obtained from the caregiver. The total score is from 0 to 144. A higher score reflects more frequency and severity of the disturbances.
| Scores on a scale | Memantine | Placebo |
|---|---|---|
| Efficacy of Memantine on Behavioural Symptoms in Outpatients With Moderate to Severe Dementia of the Alzheimer's Type Using the NPI - 12 Items Version Total Score. | -3.90 ± 1.24 | -5.13 ± 1.23 |
Change from Baseline in Severe Impairment Battery (SIB) total score. SIB is a validated scale used to assess cognitive function in patients with moderate to severe dementia. Items are single words or one-step commands combined with gestures. Nine domains are assessed, and the total score is between 0 and 100. A lower total score reflects the loss of cognitive function.
| Scores on a scale | Memantine | Placebo |
|---|---|---|
| Efficacy of Memantine on Cognition in Outpatients With Moderate to Severe Dementia of the Alzheimer's Type Using the SIB Total Score. | -2.34 ± 0.76 | -1.86 ± 0.75 |
Clinician's Interview-Based Impression of Change-Plus Version (CIBIC-plus). Improvement evaluated with reference to Baseline. CIBIC-plus is a global rating that is derived through an independent, comprehensive interview with the patient and caregiver by a rater who is barred from knowledge of all other psychometric test scores conducted as part of this protocol as well as from reported safety data. The rating is made on a 7-point scale ranging from "1 = marked improvement" to "7 = marked worsening". A score of "4" indicates no change.
| Scores on a scale | Memantine | Placebo |
|---|---|---|
| Efficacy of Memantine on Global Condition Using CIBIC-plus. | 4.68 ± 0.11 | 4.63 ± 0.11 |
Change from Baseline on the Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) 19-item version total score. ADCS-ADL- 19 items version for moderate to severe AD will measure patient's functioning. This battery of ADL questions is used here to measure the functional capabilities of patients with dementia. The inventory is done by interviewing a person in close contact with the patient and covers the most usual and consistent performance of the patient over the preceding 4 weeks. Total score is from 0 to 54. The higher score, the lower impairment.
| Scores on a scale | Memantine | Placebo |
|---|---|---|
| Efficacy of Memantine on Functioning Using ADCS-ADL - 19 Items Total Score. | -4.36 ± 0.67 | -2.56 ± 0.65 |
Change from Baseline on the Cohen-Mansfield Agitation Inventory (CMAI) - Long Form total score. CMAI - Long Form looks specifically at agitated behaviour in patients with cognitive impairment. It is a seven-point rating scale assessing the frequency of up to 29 agitated behaviours, ranging from "1 = Never" to "7 = Several times an hour". Rating is based on responses obtained from interviews with the caregiver. The total score ranges from 29 to 203, with a higher score reflecting more frequent behavioural disturbances.
| Scores on a scale | Memantine | Placebo |
|---|---|---|
| Efficacy of Memantine on Functioning Using CMAI - Long Form Total Score. | -0.26 ± 0.79 | -1.16 ± 0.79 |
Collected over Up to 28 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Memantine | — | 18/182 (9.9%) | 51/182 (28%) |
| Placebo | — | 11/187 (5.9%) | 35/187 (18.7%) |
| Event | Memantine | Placebo |
|---|---|---|
| UrosepsisInfections and infestations | 2/182 | 0/187 |
| FallInjury, poisoning and procedural complications | 2/182 | 0/187 |
| AnaemiaBlood and lymphatic system disorders | 0/182 | 2/187 |
| Atrial fibrillationCardiac disorders | 1/182 | 0/187 |
| BradyarrhythmiaCardiac disorders | 1/182 | 0/187 |
| AstheniaGeneral disorders | 1/182 | 0/187 |
| Local swellingGeneral disorders | 1/182 | 0/187 |
| Cholecystitis acuteHepatobiliary disorders | 1/182 | 0/187 |
| Acute sinusitisInfections and infestations | 1/182 | 0/187 |
| Respiratory tract infection bacterialInfections and infestations | 1/182 | 0/187 |
| Event | Memantine | Placebo |
|---|---|---|
| FallInjury, poisoning and procedural complications | 19/182 | 8/187 |
| AgitationPsychiatric disorders | 15/182 | 7/187 |
| Weight decreasedInvestigations | 11/182 | 5/187 |
| NauseaGastrointestinal disorders | 4/182 | 11/187 |
| SomnolenceNervous system disorders | 10/182 | 5/187 |
| Age Continuous(years) | Memantine | Placebo | Total |
|---|---|---|---|
| Mean | 74.7 ± 7.9 | 75.1 ± 6.9 | 74.9 ± 7.4 |
| Sex: Female, Male(Participants) | Memantine | Placebo | Total |
|---|---|---|---|
| Female | 105 | 110 | 215 |
| Male | 77 | 77 | 154 |
| NPI: Baseline Total Score(Scores on a scale) | Memantine | Placebo | Total |
|---|---|---|---|
| Mean | 30.9 ± 14.8 | 29.2 ± 13.3 | 30.1 ± 14.0 |
| SIB: Baseline Total Score(Scores on a scale) | Memantine | Placebo | Total |
|---|---|---|---|
| Mean | 82.3 ± 14.6 | 82.0 ± 12.9 | 82.1 ± 13.7 |
| CIBIC-plus: Baseline Severity Score(Scores on a scale) | Memantine | Placebo | Total |
|---|---|---|---|
| Mean | 4.4 ± 0.9 | 4.4 ± 0.9 | 4.4 ± 0.9 |
| ADCS-ADL - 19 items: Baseline Total Score(Scores on a scale) | Memantine | Placebo | Total |
|---|---|---|---|
| Mean | 35.3 ± 9.9 | 36.4 ± 8.6 | 35.8 ± 9.3 |
| CMAI - Long Form: Baseline Total Score(Scores on a scale) | Memantine | Placebo | Total |
|---|---|---|---|
| Mean | 46.8 ± 10.9 | 47.0 ± 10.9 | 46.9 ± 10.9 |
The record gives a start of Dec 2003, a primary completion of Apr 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2012, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Memantine